Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 1/2 2Phase 1 2

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

pexidartinib 1emactuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Synovitis, Pigmented Villonodular × Clear all
NCT05804045 2026-05-04

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Abbisko Therapeutics Co, Ltd

Phase 3 Active not recruiting
94 enrolled 16 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05059262 2026-03-20

MOTION

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
123 enrolled 19 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05417789 2026-02-02

TANGENT

SynOx Therapeutics Limited

Phase 3 Active not recruiting
128 enrolled

Synovitis, Synovitis, Pigmented Villonodular

NCT02371369 2022-05-11

ENLIVEN

Daiichi Sankyo

Phase 3 Completed
120 enrolled 25 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡